编者按：Osamu Yokosuka, MD, PhD, 亚太肝脏研究协会（APASL）侯任主席，日本千叶大学医学研究院教授。在本届AASLD年会上，我们有幸采访了Yokosuka主席，邀请他介绍了目前亚太地区的丙型肝炎的防治现状及明年APASL年会的筹备情况。
丙型肝炎问题仍是亚太地区沉重的健康负担
慢性HCV感染在亚太地区非常普遍，HCV感染患者的数量也非常高，它给这一地区带来了沉重的健康负担。目前亚太丙型肝炎治疗指南建议使用新型直接抗病毒药物（DAA）治疗，因为其疗效好，患者持续性病毒学应答（SVR）率非常高。DAA在治疗干扰素治疗不耐受或无应答的患者，以及老年、女性等患者中，仍可获得很高SVR率。考虑到此类药物价格还很昂贵，Yokosuka主席建议相关政府与药企之间进行协商，努力寻找机会提高患者对DAA药物的可及性。对于较年轻的患者的治疗，可以暂行等待。
Hepatitis C is very common in the Asia-Pacific region and the number of patients is very high. HCV places a heavy health burden on the region. The new antiviral agents for HCV are very efficient and achieve very high SVR rates, so the recommendation is to treat with the direct-acting antivirals. There are many patients who are interferon ineligible or interferon non-responders and even in those patients (often of older age and female), the DAAs have a high SVR rate. With regards to their high cost, I think governments should negotiate with the pharmaceutical companies where possible but where that is not the case, it is a wait-and-see situation for those younger patients.
Yokosuka主席认为IL28基因型在DAA治疗中并不具有很重要的影响。研究表明，尽管患者可能具有不利的IL28基因型，但是DAA药物仍对其具有很高的SVR率。因此，在DAA治疗时代IL28B基因型不再那么重要。
I don’t think IL28B is that important for DAA patients because data shows that even if they have a resistant IL28B genotype, the DAAs still show a high SVR rate. So IL28B is now not so important.
欢迎中国同道参加2016东京APASL年会！
2016年2月20-24日，第25届APASL年会将在东京举行。作为大会主席，Yokosuka介绍说：“中国的肝病学者的水平非常高，我诚挚地邀请大家参加2016 APASL年会，我们共同探讨肝病问题。”
Yokosuka主席具体向我们具体介绍了大会的组织情况：大会第一天为继续教育课程；第二天将集中探讨HCV相关问题；第三天将是HBV专题；最后一天是肝癌及全球肝病问题。最后，Yokosuka主席热情地说，“届时将有中国学者所关注的HBV、HCV以及肝癌领域的重要议题，我们邀请大家来到东京！”
The standard of the Chinese hepatologists is already very high so I encourage them to join us in Japan to discuss liver disease in general. The first day of the meeting will be a post-graduate course. The second day will be devoted to HCV and the third day of the meeting to HBV. The final day of the meeting will be concerned with hepatocellular carcinoma and discussions on global hepatology. The fields of HCV, HBV and HCC are topics all Chinese doctors have an interest in so please join us in Tokyo.